Prevalence of Metabolic Syndrome in Chronic Haemodialysis Patients and Its Relation to Dialysis Adequacy

Abstract

Studies show that patients with MS have a 2.5-fold higher risk of developing CKD. Studies suggest that the renal fibrosis seen in MS might be caused by a constellation of insulin resistance, hypertension, dyslipidemias and inflammation, and result in a heightened expression of adipocytokines, angiotensin and inflammatory cytokines such as interleukin-6 and tumor necrosis factor alpha This study aimed to determine the prevalence and the most common factor of metabolic syndrome in hemodialysis patients and evaluate the relation of metabolic syndrome to dialysis adequacy. This study was carried out on 75 Patients 16 years of age and older who had been receiving hemodialysis for more than 6 months and 50 apparently healthy individuals as control. The patients were recruited from hemodialysis unit at Esna Hospital from June 2012 to January 2013. Metabolic syndrome was defined according to the ATP III criteria. Hemodialysis was done in 4 hourly thrice weekly session for each patient with renal failure Patients were excluded if: they were candidates for kidney transplantation before completing 6 months of hemodialysis or if they were assumed to have a life expectancy of less than 6 months, patients known to have type 1 diabetes mellitus or familial dyslipidemia or Patients with known diseases or receiving drugs that disturb glucose or lipid metabolism such as thiazide diuretics, beta blockers, Cushing's syndrome and nephrotic syndrome.